Eiji Toyota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eiji Toyota has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Takahiro Kawamoto
Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan
3 shared publications- Hiroyuki Okura
Department of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan
2 shared publications Kiyoshi Yoshida
Department of Cardiology, Kawasaki Medical School, Kurashiki, Okayama, Japan
2 shared publications- Kiyoshi Yoshida
Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan
2 shared publications Koichiro Imai
Department of Cardiology, Kawasaki Medical School, Kurashiki, Okayama, Japan
2 shared publicationsNozomi Watanabe
2 shared publications
Latest Publications
- Open Access
- 1 January 2010
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 51 (2) , 178-186
Diagnosis of Myocardial Viability by Fluorodeoxyglucose Distribution at the Border Zone of a Low Uptake Region
Toyota E, et al. Yonsei Med J. 2010 Mar;51(2):178-186. http://dx.doi.org/10.3349/ymj.2010.51.2.178
- 1 January 2010
- Published by Yonsei University College of Medicine in Yonsei Medical Journal
- Vol. 51 (2) , 178-186
Open AccessDiagnosis of Myocardial Viability by Fluorodeoxyglucose Distribution at the Border Zone of a Low Uptake Region
Toyota E, et al. Yonsei Med J. 2010 Mar;51(2):178-186. http://dx.doi.org/10.3349/ymj.2010.51.2.178
- 30 August 2009
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 36 (9) , e20-e25
DEVELOPMENT OF CARDIAC DYSFUNCTION INDUCED BY REPETITIVE TRANSIENT MYOCARDIAL ISCHAEMIA IS INHIBITED BY EDARAVONE IN CONSCIOUS RATS
SUMMARY: In the present study, we investigated the effects of treatment with the hydroxyl radical scavenger 3‐methyl‐1‐phenyl‐2‐pyrazolin‐5‐one (edaravone) on myocardial dysfunction induced by transient but frequent ischaemia in conscious rats. Conscious male Wistar rats were subjected to repetitive ischaemia (RI; 40 s ischaemia every 20 min for 72 h). After the ninth episode of RI, edaravone (1 mg/kg, i.v., at each ischaemic event) or vehicle control (acetate buffer solution, i.v.) was administered. Dilation of the left ventricle (LV) after the eighth RI (fractional area change; %FACinitial) and after the final RI (%FACfinal) was determined by comparing measurements (12 MHz echocardiogram) at these time‐points with baseline LV area prior to RI. In controls, %FACfinalwas correlated with %FACinitial(r = 0.98;P < 0.0001), making %FACinitiala predictor of %FACfinal. Edaravone treatment shifted the %FACinitial–%FACfinalrelationship downward (P < 0.0001), indicating that edaravone inhibited progression of LV dilation. In addition, %FACfinalwas correlated with myocardial generation of reactive oxygen species (ROS) in control samples (r = 0.88,P = 0.008), although both %FACfinaland ROS were suppressed by edaravone treatment (P = 0.016). We conclude that repetitive transient ischaemia in conscious rats induced development of cardiac dysfunction and that this phenomenon was inhibited by edaravone. We speculate that edaravone is a potential therapeutic agent that may interfere with the progression of cardiac dysfunction in high‐risk patients with RI.
- 30 August 2009
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 36 (9) , e20-e25
DEVELOPMENT OF CARDIAC DYSFUNCTION INDUCED BY REPETITIVE TRANSIENT MYOCARDIAL ISCHAEMIA IS INHIBITED BY EDARAVONE IN CONSCIOUS RATS
SUMMARY: In the present study, we investigated the effects of treatment with the hydroxyl radical scavenger 3‐methyl‐1‐phenyl‐2‐pyrazolin‐5‐one (edaravone) on myocardial dysfunction induced by transient but frequent ischaemia in conscious rats. Conscious male Wistar rats were subjected to repetitive ischaemia (RI; 40 s ischaemia every 20 min for 72 h). After the ninth episode of RI, edaravone (1 mg/kg, i.v., at each ischaemic event) or vehicle control (acetate buffer solution, i.v.) was administered. Dilation of the left ventricle (LV) after the eighth RI (fractional area change; %FACinitial) and after the final RI (%FACfinal) was determined by comparing measurements (12 MHz echocardiogram) at these time‐points with baseline LV area prior to RI. In controls, %FACfinalwas correlated with %FACinitial(r = 0.98;P < 0.0001), making %FACinitiala predictor of %FACfinal. Edaravone treatment shifted the %FACinitial–%FACfinalrelationship downward (P < 0.0001), indicating that edaravone inhibited progression of LV dilation. In addition, %FACfinalwas correlated with myocardial generation of reactive oxygen species (ROS) in control samples (r = 0.88,P = 0.008), although both %FACfinaland ROS were suppressed by edaravone treatment (P = 0.016). We conclude that repetitive transient ischaemia in conscious rats induced development of cardiac dysfunction and that this phenomenon was inhibited by edaravone. We speculate that edaravone is a potential therapeutic agent that may interfere with the progression of cardiac dysfunction in high‐risk patients with RI.
- 1 January 2008
- Vol. 17 (1) , 89-93
Mechanism of increasing systolic coronary flow velocity in patients with aortic regurgitation.
The mechanism of increasing systolic coronary flow velocity of the epicardial coronary artery in patients with aortic regurgitation (AR) has not been well investigated. Thus, an evaluation was made of the flow velocity pattern of the epicardial coronary artery in these patients. In 12 patients with AR, epicardial coronary flow velocity was monitored using Doppler guidewire, and diameter changes of the epicardial coronary artery using intravascular ultrasound (IVUS). The systolic coronary vascular resistance in AR patients was significantly less than that in controls (1.8 +/- 0.9 versus 3.3 +/- 0.7 mmHg/ml/min; p <0.01). Likewise, area and diameter changes of the epicardial coronary artery during the cardiac cycle in AR patients were significantly less than those in controls (102 +/- 1% versus 106 +/- 4%; p <0.01; and 102 +/- 1% versus 106 +/- 4%; p = 0.03). In patients with AR, the increase in systolic coronary flow velocity of the epicardial coronary artery during the systolic phase was considered to result from a major coronary perfusion of blood into the intramyocardial vessels (which showed a decreased resistance), rather than it being stored in the epicardial coronary artery.
- 1 January 2008
- Vol. 17 (1) , 89-93
Mechanism of increasing systolic coronary flow velocity in patients with aortic regurgitation.
The mechanism of increasing systolic coronary flow velocity of the epicardial coronary artery in patients with aortic regurgitation (AR) has not been well investigated. Thus, an evaluation was made of the flow velocity pattern of the epicardial coronary artery in these patients. In 12 patients with AR, epicardial coronary flow velocity was monitored using Doppler guidewire, and diameter changes of the epicardial coronary artery using intravascular ultrasound (IVUS). The systolic coronary vascular resistance in AR patients was significantly less than that in controls (1.8 +/- 0.9 versus 3.3 +/- 0.7 mmHg/ml/min; p <0.01). Likewise, area and diameter changes of the epicardial coronary artery during the cardiac cycle in AR patients were significantly less than those in controls (102 +/- 1% versus 106 +/- 4%; p <0.01; and 102 +/- 1% versus 106 +/- 4%; p = 0.03). In patients with AR, the increase in systolic coronary flow velocity of the epicardial coronary artery during the systolic phase was considered to result from a major coronary perfusion of blood into the intramyocardial vessels (which showed a decreased resistance), rather than it being stored in the epicardial coronary artery.
- 1 October 2007
- Vol. 50 (4) , 223-8
Histological characteristics of plaque with ultrasonic attenuation: a comparison between intravascular ultrasound and histology.
Intermediate echogenic plaque without acoustic shadow on intravascular ultrasound (IVUS) imaging has been recognized as fibrous plaque. Such echogenic plaque with ultrasonic attenuation may have higher risk for distal flow disturbance (slow flow/no-reflow) during percutaneous coronary intervention. However, histological evaluation of plaque with ultrasonic attenuation has not been performed. This study evaluated the histological characteristics of plaque with ultrasonic attenuation assessed by IVUS. By using IVUS, 36 samples of human cadaveric coronary arterial echogenic plaque (percentage plaque area > 40%) without calcium were selected, and classified into the attenuation group; plaque with ultrasonic attenuation, and the non-attenuation group; plaque without attenuation. These plaques were classified for fibrous, fibrofatty, calcium, and necrotic core areas by histological examination. True fibrous plaque was found in 91.7% of the non-attenuation group, but only 68.0% of the attenuation group (p < 0.01) . On the other hand, the percentage fibrofatty and necrotic core plaque areas in the attenuation group were significant larger than those in the non-attenuation group (fibrofatty: 16.3 +/- 13.8% vs. 2.7 +/- 3.1%, p < 0.01; necrotic core: 13.0 +/- 19.4% vs. 3.9 +/- 8.0%, p = 0.03). CONCLUSIONS. Plaque with ultrasonic attenuation contains more fibrofatty tissue and necrotic core compared to fibrous plaque without attenuation.
- 1 October 2007
- Vol. 50 (4) , 223-8
Histological characteristics of plaque with ultrasonic attenuation: a comparison between intravascular ultrasound and histology.
Intermediate echogenic plaque without acoustic shadow on intravascular ultrasound (IVUS) imaging has been recognized as fibrous plaque. Such echogenic plaque with ultrasonic attenuation may have higher risk for distal flow disturbance (slow flow/no-reflow) during percutaneous coronary intervention. However, histological evaluation of plaque with ultrasonic attenuation has not been performed. This study evaluated the histological characteristics of plaque with ultrasonic attenuation assessed by IVUS. By using IVUS, 36 samples of human cadaveric coronary arterial echogenic plaque (percentage plaque area > 40%) without calcium were selected, and classified into the attenuation group; plaque with ultrasonic attenuation, and the non-attenuation group; plaque without attenuation. These plaques were classified for fibrous, fibrofatty, calcium, and necrotic core areas by histological examination. True fibrous plaque was found in 91.7% of the non-attenuation group, but only 68.0% of the attenuation group (p < 0.01) . On the other hand, the percentage fibrofatty and necrotic core plaque areas in the attenuation group were significant larger than those in the non-attenuation group (fibrofatty: 16.3 +/- 13.8% vs. 2.7 +/- 3.1%, p < 0.01; necrotic core: 13.0 +/- 19.4% vs. 3.9 +/- 8.0%, p = 0.03). CONCLUSIONS. Plaque with ultrasonic attenuation contains more fibrofatty tissue and necrotic core compared to fibrous plaque without attenuation.